- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Foster City Today
By the People, for the People
Nordea Investment Boosts Gilead Sciences Stake
Nordea Investment Management AB increases its position in the biopharmaceutical company by 16.5% in Q4 2025.
Mar. 22, 2026 at 10:07am
Got story updates? Submit your updates here. ›
Nordea Investment Management AB, a major investment firm, increased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 16.5% in the fourth quarter of 2025, according to a recent SEC filing. The fund now owns 5,138,699 shares of the biopharmaceutical company's stock, worth approximately $630 million.
Why it matters
Gilead Sciences is a prominent biopharmaceutical company known for its antiviral therapies, particularly in the areas of HIV and viral hepatitis. Nordea's increased investment in the company suggests confidence in Gilead's future prospects and the potential for continued growth.
The details
Nordea Investment Management AB purchased an additional 726,101 shares of Gilead Sciences during the fourth quarter, bringing its total ownership to approximately 0.41% of the company's outstanding shares. The investment firm cited Gilead's strong product portfolio and pipeline as factors contributing to its decision to increase its position in the company.
- Nordea Investment Management AB increased its Gilead Sciences holdings in the fourth quarter of 2025.
The players
Nordea Investment Management AB
A major investment firm that manages assets on behalf of institutional and retail clients.
Gilead Sciences, Inc.
A biopharmaceutical company focused on the discovery, development, and commercialization of medicines in areas of high unmet medical need, particularly in antiviral therapies for HIV and viral hepatitis.
The takeaway
Nordea's increased investment in Gilead Sciences reflects the firm's confidence in the biopharmaceutical company's long-term growth potential. As a prominent player in the antiviral therapy market, Gilead's continued success could have implications for the broader healthcare industry and the investment landscape.
